This is the authors' abstract. We don't add key points for this paper.
The structural integrity of inhalable liposomal carriers is a key determinant of drug release behavior, pulmonary residence time, and therapeutic efficacy. This study aimed to establish a compensated Förster resonance energy transfer (FRET)-based platform for the quantitative assessment of liposome integrity throughout the inhalation delivery process. By compensation for donor fluorescence bleed-through and direct acceptor excitation, the method enables accurate quantification of FRET signals from liposomes co-loaded with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate (DiD, donor)/1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR, acceptor), using both spectrofluorometry and macroscopic imaging. Upon treatment with Triton X-100, decreases in the compensated FRET/donor ratio were detected at lower concentrations than those required to induce measurable changes in membrane anisotropy and within the same concentration range as the onset of encapsulated 6-carboxyfluorescein release. Using this platform, in vitro aerosol characterization with an Andersen cascade impactor enabled simultaneous analysis of aerodynamic particle size distribution and stage-specific liposome integrity. In vivo experiments in mice-including ex vivo lung imaging and bronchoalveolar lavage fluid analysis-revealed a time-dependent decline in liposome integrity during pulmonary residence. This ability to monitor carrier structural stability from initial deposition through residence-an aspect not readily achieved with conventional single-fluorophore labeling-offers significant advantages for formulation development, stabilization strategies, and dosing regimen optimization. The FRET-based platform could, in principle, be adapted for use with other standardized cascade impactors such as the Next Generation Impactor and is expected to be applicable to a wide range of lipid-based or polymeric nanocarriers, including inhalable vaccines and nucleic acid therapeutics.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Togami et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: